Another study identified a prognostic protein biomarker, ADH1A (oxidoreductase activity), associated with metabolic reprogramming, and HCC with high ADH1A showed reduced TP53 mutations and lower AFP levels92. The gene discussed is ADH1A; the disease is hepatocellular carcinoma.